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MEK INHIBITION RESULTS IN SELECTIVE IMMUNOSUPPRESSION OF
HUMAN T CELLS AND DECREASES CYTOKINE PRODUCTION IN A
MEMORY STAGE-DEPENDENT MANNER
Kim, T.K.1,2, Valencia Gattas, M.1, Benjamin, C.L.1, Levy, R.B1,
Wieder, E.D.1, Komanduri, K.V.1,2 1University of Miami Sylvester Can-
cer Center, Miami, FL; 2M.D. Anderson Cancer Center, Houston, TX
Although allogeneic stem cell transplantation is a treatment of
choice for many hematologic malignancies, a key complication is
graft-versus-host disease (GVHD). Although currently used immu-
nosuppressive medications may successfully inhibit GVHD, none
are selective enough to spare pathogen-specific T cells, leading to
an increased risk of life-threatening infections (e.g., CMV reactiva-
tion). Recent studies suggest that naive and early memory T cells
may be relatively more potent at inducing GVHD, whereas we and
others have shown that most CMV-specific T cells exist as relatively
differentiated cells. Therefore, we reasoned that differences in sig-
naling could be used to selectively inhibit certain maturation stages
of human T cells. Since the MAPK pathway has been demonstrated
to be important for cytokine production in T cells, we measured
phospho-Erk1/2 (p-Erk) in PMA:Ionomycin-treated or SEB-
stimulated CD4+ and CD8 +T cell maturation subsets by flow
cytometry. Naive (CD27 + CD45RA+) and early memory (M1,
CD27 + CD45RA-) T cells expressed three-fold higher p-Erk than
intermediate (M2, CD27-CD45RA-) and late memory (M3,
CD27-CD45RA+) T cells (P\0.05). To test the hypothesis that
the effects of MEK inhibition depend on p-Erk expression, we stim-
ulated T cells from healthy donors using allogeneic dendritic cells
(DC) and assessed alloactivation in the presence or absence of the
MEK inhibitor U0126. U0126-treated CD4+ and CD8 +T cells
were 60-70% less activated than DMSO-treated cells, as assessed
both by CD38 upregulation and CFSE dilution. Nextwedetermined
whether U0126 selectively suppresses cytokine production in a stage-
dependent manner. We stimulated PBMC from healthy subjects
(n5 7) with SEB in the presence of U0126 and measured IL-2,
IFNg and TNFa production in T cell maturation subsets. In
CD4 +T cells, both IL-2 and TNFa production were significantly
more suppressed in naive and early memory cells (Table 1). In CD8+
cells, we similarly saw reductions in IFNg and TNFa production fol-
lowing MEK inhibition (Table 1). Preliminary experiments also sug-
gest that U0126 only minimally suppresses of CMV pp65-specific T
cells from healthy subjects (n5 3), although additional confirmation
is needed. These data demonstrate thatMEK inhibition preferentially
inhibits naive and early memory cells critical for GVHD initiation
while sparing late-memory CMV-specific cells, providing the basis
for more selective clinical strategies for GVHD inhibition.Mean percent reduction in cytokine production in response to
U0126 (n5 7)
Cell Cytokine N M1 M2 M3
CD41 IL-2 79% 56% 50% **
CD41 TNFa 87% 62% 48% **
CD81 IFNg 58% 30% 15% 0%
CD81 TNFa 70% 55% 38% 5%
*all P\0.05 for CD4: N vs. M1, M1 vs. M2, CD8: N vs. M1, M1 vs. M2,
M2 vs. M3.
**M3 cells are not significantly present in CD41 cells.392
STATINS INHIBIT THE ANTIGEN-PRESENTING FUNCTION OF HUMAN B
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Statins are lipid-lowering drugs that reduce cholesterol produc-
tion by inhibiting HMG-CoA-reductase the rate-limiting enzymeof the mevalonate pathway. Besides their lipid-lowering effect statins
possess potent immunomodulatory activity. Apart from T cells sev-
eral other immune cells, including B cells, have been shown to be in-
volved in the pathophysiology of graft-versus-host disease (GVHD).
We conducted a expression analysis which showed that the genes of
the mevalonate pathway were upregulated following activation of
human B cells via CD40. Therefore we tested whether statins could
inhibit the activation and antigen-presenting function of B cells as
well as their ability to stimulate the proliferation of allogeneic T
cells. Addition of simvastatin led to a dose-dependent inhibition of
B cell activation and proliferation following stimulation via CD40.
The upregulation of important costimulatory molecules such as
CD80 and CD86 as well as MHC class II was significantly reduced
when simvastatin was added to co-cultures of purified human B cells
with CD40 ligand-expressing fibroblasts. As a consequence the pro-
liferation of allogeneic T cells in response to simvastatin-treated
CD40-activated B cells was significantly decreased compared to un-
treated controls. Addition of atorvastatin had similar effects on
CD40-activated B cells. Surprisingly, the hydrophilic statin pravas-
tatin had no significant effects on B cell activation and antigen-pre-
senting function. Importantly, the doses of simvastatin that were
required for inhibition of the antigen presenting function of B cells
were at least one order of magnitude lower than those required to in-
hibit T cell activation and proliferation induced by anti-CD3/anti-
CD28-coated beads. These results therefore suggest that inhibition
of antigen-presenting cells is an important mechanism by which sta-
tins mediate their immunomodulatory effects. Furthermore, the
observation that pravastatin had no significant effect on antigen-
presenting function has important clinical implications and indicates
that hydrophilic statins like simvastatin should be prefered in future
clinical trials assessing the impact of statins on GVHD.
In summary, our findings demonstrate that statins are promising
immunodulatory agents for the prevention and treatment of
GVHD.This notion is supported by the results of recent clinial trials
which found a reduction in acute and chronic GVHD in patients
which were treated with statins.393
PRIMARY HUMAN ACUTE MYELOID LEUKEMIA STEM CELLS SHOW
REDUCED SENSITIVITY TO NATURAL KILLER CELL-MEDIATED KILLING
Gill, S.1, Majeti, R.2, Bowler, M.1, Negrin, R.S.1 1Stanford University,
Stanford, CA; 2Stanford University, Palo Alto, CA
Introduction:Relapse after initial response to treatment of acute
myeloid leukemia (AML) may be due to the persistence of leu-
kemia stem cells (LSC), which show resistance to chemotherapy.
Currently, the optimal approach to the targeting of LSC is un-
known. In this study, we sought to investigate the potential
graft-versus-leukemia effect of allogeneic natural killer (NK)
cells on AML LSC using immunophenotypic and functional
studies.
Methods: Samples were obtained from the peripheral blood of 11
newly diagnosed patients with AML, under an institutional re-
view board-approved protocol. AML sub-populations were de-
fined based on expression of CD34 and CD38. Initial analysis
included cytofluorometric immunophenotyping of the NK recep-
tor ligand molecules MICA/B, CD112, CD155, HLA-E, MHC
class I, CD48, Fas, DR4 and DR5 in the different AML sub-
populations. Of the 11 samples analysed, four contained an
indentifiable distinct CD34 + CD38- population (defined immu-
nophenotypically as LSC compared to the more mature popula-
tion with the phenotype of CD34 + CD38+), and these were
selected for functional studies. Subpopulations were separated us-
ing fluorescence-activated cell sorting and incubated with effec-
tors (interleukin-2 stimulated purified allogeneic NK cells and
the NK-92 cell line).
Results: Analysis of NK receptor ligands revealed non-significantly
lower expression amongst the LSC population of the activating
NKG2D ligands MICA/B (mean 10.9% +- 2.0 vs 34.7% +- 11.8,
p5 0.16) as well as of the 2B4 ligand CD48 (mean 0.5% +- 0.2 vs
10.3% +- 4.9, p5 0.15). Using a panel of four different effectors,
the putative LSC population and the non-LSC blast population
were found to respond differentially to NK cell-mediated cytototox-
icity, with caspase activation (as a measure of apoptosis) in the blast
